- Home
- MGEE vs BEAM Comparison
MGEE vs BEAM Comparison
Compare MGEE & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGEE | BEAM |
|---|---|---|
| Founded | 1855 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MGEE | BEAM |
|---|---|---|
| Price | $78.16 | $29.31 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $80.50 | $50.75 |
| AVG Volume (30 Days) | 141.6K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | 11.71 | ★ 82.31 |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $2.77 | $33.77 |
| P/E Ratio | $59.36 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $72.16 | $16.03 |
| 52 Week High | $87.94 | $38.26 |
Technical Indicators
Market Signals| Indicator | MGEE | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 53.83 |
| Support Level | $78.03 | $28.40 |
| Resistance Level | $82.01 | $34.20 |
| Average True Range (ATR) | 1.24 | 1.36 |
| MACD | -0.27 | 0.46 |
| Stochastic Oscillator | 16.02 | 66.66 |
Price Performance
Historical ComparisonAbout MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.